Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

Johnson, Philip J.; Zhou, Qing; Dao, Doan Y.; Lo, Y.M. Dennis

doi:10.1038/s41575-022-00620-y

Cited by 152 publications

(109 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCC is a primary liver cancer with a high mortality rate and represents the most common malignancy worldwide, especially in Asia, Africa, and southern Europe ( Johnson et al, 2011 ; Kawano et al, 2012 ). Viral hepatitis (hepatitis B or C), cirrhosis, diabetes mellitus, and chronic alcoholism are the most common causes of HCC ( Johnson et al, 2022 ; Salem et al, 2022 ). Tumor size and stage are the two key factors affecting the treatment and prognosis of HCC, and the prognosis of advanced HCC is poor.…”

Section: Adenosine Signaling In the Livermentioning

confidence: 99%

Caffeine in liver diseases: Pharmacology and toxicology

et al. 2022

View full text Add to dashboard Cite

We have previously shown that adenosine A1AR antagonists, adenosine A2aAR antagonists, and caffeine have significant inhibitory effects on the activation and proliferation of hepatic stellate cells in alcoholic liver fibrosis. Many recent studies have found that moderate coffee consumption is beneficial for various liver diseases. The main active ingredient of coffee is caffeine, which is a natural non-selective adenosine receptor antagonist. Moreover, numerous preclinical epidemiological studies and clinical trials have examined the association between frequent coffee consumption and the risk of developing different liver diseases. In this review, we summarize and analyze the prophylactic and therapeutic effects of caffeine on various liver diseases, with an emphasis on cellular assays, animal experiments, and clinical trials. To review the prevention and treatment effects of caffeine on different liver diseases, we searched all literature before 19 July 2022, using “caffeine” and “liver disease” as keywords from the PubMed and ScienceDirect databases. We found that moderate coffee consumption has beneficial effects on various liver diseases, possibly by inhibiting adenosine binding to its receptors. Caffeine is a potential drug for the prevention and treatment of various liver diseases.

show abstract

Section: Adenosine Signaling In the Livermentioning

confidence: 99%

Caffeine in liver diseases: Pharmacology and toxicology

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Although not yet implemented in routine clinical practice, studies on biomarkers show very promising results, and might lead to an earlier diagnosis in HBC patients in the upcoming years [52,53].…”

Section: Discussionmentioning

confidence: 99%

Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018

Hucke

Pinter

Hucke

et al. 2022

Cancers

View full text Add to dashboard Cite

Using national registries, we investigated the epidemiological trends of hepatobiliary carcinomas in Austria between 2010 and 2018 and compared them to those reported for the periods of 1990–1999 and 2000–2009. In total, 12,577 patients diagnosed with hepatocellular carcinoma (n = 7146), intrahepatic cholangiocarcinoma (n = 1858), extrahepatic cholangiocarcinoma (n = 1649), gallbladder carcinoma (n = 1365), and ampullary carcinoma (n = 559), between 2010 and 2018, were included. The median overall survival of all patients was 9.0 months. The best median overall survival was observed in patients with ampullary carcinoma (28.5 months) and the worst median overall survival was observed in patients with intrahepatic carcinoma (5.6 months). The overall survival significantly improved in all entities over the period 2010–2018 as compared with over the periods of 2000–2009 and 1990–1999. Age-adjusted incidence and mortality rates remained stable for most entities in both, men and women; only in gallbladder carcinoma, the incidence and mortality rates significantly decreased in women, whereas, in men, the incidence rates remained stable and mortality rates showed a decreasing trend. We showed that age-adjusted incidence and mortality rates were stable in most entities, except in gallbladder carcinoma. The overall survival improved in almost all entities as compared with those during 1990–2009.

show abstract

“…In the HCC context, several proteins were identified as TAAs such as: AFP, new york esophageal squamous cell carcinoma-1 (NY-ESO-1), synovial sarcoma X breakpoint 2 (SSX-2), melanoma antigen gene (MAGE), midkine (MDK), hypoxia-inducible factor-1α and -2α (HIF-1α and HIF-2α), epithelial cell adhesion molecule (EpCAM), asialoglycoprotein receptor (ASGPR), transferrin receptor 1 (TfR1), folic acid receptor (FR), scavenger receptor class B type I (SR-B1), mucin-1 (MUC1), carcinoembryonic antigen (CEA), prostate-specific membrane antigen (PSMA), tumor endothelial marker 1 (TEM1), phosphatases of regenerating liver-1 and -3 (PRL-1 and PRL3), cluster of differentiation 147 (CD147), roundabout homolog 1 (ROBO1), programmed death-ligand 1 and 2 (PD-L1 and PD-L2), and GPC3 [ 38 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 ]. AFP protein is detected during embryonic development, but its level decreased after birth.…”

Section: Tumor-associated Antigens Useful For Hcc Treatmentmentioning

confidence: 99%

“…AFP protein is detected during embryonic development, but its level decreased after birth. It is a marker of liver pathologies, including malignant lesions such as HCC, showing an increase in its levels during liver diseases [ 92 ]. NY-ESO-1 is part of the cancer-testis antigens family and its mRNA expression was detected in 14.1% of HCC tumor tissues [ 93 ].…”

Section: Tumor-associated Antigens Useful For Hcc Treatmentmentioning

confidence: 99%

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies

Mossenta

Busato

et al. 2022

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the second most lethal tumor, with a 5-year survival rate of 18%. Early stage HCC is potentially treatable by therapies with curative intent, whereas chemoembolization/radioembolization and systemic therapies are the only therapeutic options for intermediate or advanced HCC. Drug resistance is a critical obstacle in the treatment of HCC that could be overcome by the use of targeted nanoparticle-based therapies directed towards specific tumor-associated antigens (TAAs) to improve drug delivery. Glypican 3 (GPC3) is a member of the glypican family, heparan sulfate proteoglycans bound to the cell surface via a glycosylphosphatidylinositol anchor. The high levels of GPC3 detected in HCC and the absence or very low levels in normal and non-malignant liver make GPC3 a promising TAA candidate for targeted nanoparticle-based therapies. The use of nanoparticles conjugated with anti-GPC3 agents may improve drug delivery, leading to a reduction in severe side effects caused by chemotherapy and increased drug release at the tumor site. In this review, we describe the main clinical features of HCC and the common treatment approaches. We propose the proteoglycan GPC3 as a useful TAA for targeted therapies. Finally, we describe nanotechnology approaches for anti-GPC3 drug delivery systems based on NPs for HCC treatment.

show abstract

Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

Cited by 152 publications

References 137 publications

Caffeine in liver diseases: Pharmacology and toxicology

Caffeine in liver diseases: Pharmacology and toxicology

Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies

Contact Info

Product

Resources

About